The SEQTEST Procedure

The following example illustrates a clinical study that uses a two-sided O’Brien-Fleming design (O’Brien and Fleming, 1979) to stop the trial early for ethical concerns about possible harm or for unexpectedly strong efficacy of the new drug.

Suppose that a pharmaceutical company is conducting a clinical trial to test the efficacy of a new cholesterol-lowering drug. The primary focus is low-density lipoprotein (LDL), the so-called bad cholesterol, which is a risk factor for coronary heart disease. LDL is measured in mg / dL, milligrams per deciliter of blood.

The trial consists of two groups of equally allocated patients with elevated LDL level: an experimental group given the new drug and a placebo control group. Suppose the changes in LDL level after the treatment for patients in the experimental and control groups are normally distributed with means and , respectively, and have a common variance . Then the null hypothesis of no effect for the new drug is . Also suppose that the alternative reference is the clinically meaningful difference that the trial should detect with a high probability (power), and that a good estimate of the standard deviation for the changes in LDL level is .

The following statements invoke the SEQDESIGN procedure and request a four-stage O’Brien-Fleming design for standardized normal test statistics:

ods graphics on;
proc seqdesign altref=-10.0;
   TwoSidedOBrienFleming: design nstages=4
                          method=obf
                          ;
   samplesize model=twosamplemean(stddev=20);
   ods output Boundary=Bnd_LDL;
run;
ods graphics off;

The ALTREF= option specifies the alternative reference, and the actual maximum information is derived in the SEQDESIGN procedure.

In the DESIGN statement, the label TwoSidedOBrienFleming identifies the design in the output tables. By default (or equivalently if you specify ALT=TWOSIDED and STOP=REJECT), the design has a two-sided alternative hypothesis with early stopping in the interim stages only to reject the null hypothesis. That is, at each interim stage, the trial will either be stopped to reject the null hypothesis or continue to the next stage.

The NSTAGES=4 option in the DESIGN statement specifies the total number of stages in the group sequential trial, including three interim stages and a final stage. In the SEQDESIGN procedure, the null hypothesis for the design is . By default (or equivalently if you specify ALPHA=0.05 and BETA=0.10), the design has a Type I error probability , and a Type II error probability , which corresponds to a power of at the alternative reference .

For a two-sided design with early stopping to reject the null hypothesis, there are two boundaries for the design: an upper (rejection) boundary that consists of upper rejection critical values and a lower boundary that consists of lower rejection critical values. Each boundary is a set of critical values, one from each stage. With the METHOD=OBF option in the DESIGN statement, the O’Brien-Fleming method is used for the two boundaries for the design; see Figure 84.5.

The SAMPLESIZE statement with the MODEL=TWOSAMPLEMEAN option uses the derived maximum information to compute required sample sizes for a two-sample test for mean difference.

The ODS OUTPUT statement with the BOUNDARY=BND_LDL option creates an output data set named BND_LDL which contains the resulting boundary information. At each stage of the trial, data are collected and analyzed with a statistical procedure, and a test statistic and its corresponding information level are computed.

In this example, you can use the REG procedure to compute the maximum likelihood estimate for the drug effect and the corresponding standard error for . At stage 1, you can use the SEQTEST procedure to compare the test statistic with adjusted boundaries that are derived from the boundary information stored in the BOUND_LDL data set. At each subsequent stage, you can use the SEQTEST procedure to compare the test statistic with adjusted boundaries that are derived from the boundary information stored in the test information table that was created by the SEQTEST procedure at the previous stage. The test information tables are structured for input to the SEQTEST procedure.

At each interim stage, the trial will either be stopped to reject the null hypothesis or continue to the next stage. At the final stage, the null hypothesis is either rejected or accepted.

By default (or equivalently if you specify INFO=EQUAL), the SEQDESIGN procedure derives boundary values with equally spaced information levels for all stages—that is, the same information increment between successive stages.

The “Design Information” table in Figure 84.3 displays design specifications and three derived statistics: the maximum information, the average sample number under the null hypothesis (Null Ref ASN), and the average sample number under the alternative hypothesis (Alt Ref ASN). Each statistic is expressed as a percentage of the identical statistic for the corresponding fixed-sample information. The average sample number is the expected sample size (for nonsurvival data) or expected number of events (for survival data). When you specify an alternative reference (in this case, ALTREF=–10), the actual maximum information 0.1074 is also computed. Note that for a symmetric two-sided design, the ALTREF=–10 option implies a lower alternative reference of –10 and an upper alternative reference of 10.

The “Boundary Information” table in Figure 84.4 displays the information level, the lower and upper alternative references, and the lower and upper boundary values at each stage. By default (or equivalently if you specify INFO=EQUAL), the SEQDESIGN procedure uses equally spaced information levels for all stages.

The information proportion is the proportion of maximum information available at each stage. By default (or equivalently if you specify BOUNDARYSCALE=STDZ), the alternative references and boundary values are displayed with the standardized Z statistic scale. The alternative reference in the standardized Z scale at stage k is given by , where is the alternative reference and is the information available at stage k, k = 1, 2, 3, 4.

In this example, a standardized Z statistic is computed by standardizing the parameter estimate of the effect in LDL level. A lower Z test statistic indicates a beneficial effect. Consequently, at each interim stage, if the standardized Z test statistic is less than or equal to the corresponding lower boundary value, the hypothesis is rejected for efficacy. If the test statistic is greater than or equal to the corresponding upper boundary value, the hypothesis is rejected for harmful effect. Otherwise, the process continues to the next stage. At the final stage (stage 4), the hypothesis is rejected for efficacy if the Z statistic is less than or equal to the corresponding lower boundary value –2.0243, and the hypothesis is rejected for harmful effect if the Z statistic is greater than or equal to the corresponding upper boundary value 2.0243. Otherwise, the hypothesis of no significant difference is accepted.

Note that in a typical trial, the actual information levels do not match the information levels specified in the design. Consequently, the SEQTEST procedure modifies the boundary values stored in the BND_LDL data set to adjust for these new information levels.

If ODS Graphics is enabled, a detailed boundary plot with the rejection and acceptance regions is displayed, as shown in Figure 84.5.

This boundary plot displays the boundary values in the “Boundary Information” table in Figure 84.4. The stages are indicated by vertical lines with accompanying stage numbers. The horizontal axis indicates the information levels for the stages. If a test statistic at an interim stage is in the rejection region (shaded area), the trial stops and the null hypothesis is rejected. If the statistic is not in any rejection region, the trial continues to the next stage. The plot also displays critical values for the corresponding fixed-sample design. The symbol “” identifies the fixed-sample critical values of –1.96 and 1.96.

When you specify the SAMPLESIZE statement, the maximum information (either explicitly specified or derived in the SEQDESIGN procedure) is used to compute the required sample sizes for the study. The MODEL=TWOSAMPLEMEAN(STDDEV=20) option specifies the test for the difference between two normal means. See the section “Test for the Difference between Two Normal Means” in the chapter “The SEQDESIGN Procedure” for a detailed description of how these required sample sizes are calculated.

The “Sample Size Summary” table in Figure 84.6 displays the parameters for the sample size computation and the resulting maximum and expected sample sizes.

With the derived maximum information 0.1074 and the specified MODEL=TWOSAMPLEMEAN (STDDEV=20) option in the SAMPLESIZE statement, the total sample size in each group is

The “Sample Sizes (N)” table in Figure 84.7 displays the required sample sizes at each stage for the trial, in both fractional and integer numbers. The derived fractional sample sizes are displayed under the heading “Fractional N.” These sample sizes are rounded up to integers under the heading “Ceiling N.” By default (or equivalently if you specify WEIGHT=1 in the MODEL=TWOSAMPLEMEAN option), the sample sizes for the two groups are equal for the two-sample test.

In practice, integer sample sizes are used in the trial, and the resulting information levels increase slightly. Thus, each of the two groups needs 22, 43, 65, and 86 patients for the four stages, respectively.

Suppose that 22 patients are available in each group at stage 1 and that their measurements for LDL are saved in the data set LDL_1. Figure 84.8 lists the first 10 observations in the data set LDL_1.

The variable Trt is an indicator variable with value 1 for patients in the treatment group and value 0 for patients in the placebo control group. The variable Ldl is the LDL level of these patients.

The following statements use the REG procedure to estimate the mean treatment difference and its associated standard error at stage 1:

proc reg data=LDL_1;
   model Ldl=Trt;
   ods output ParameterEstimates=Parms_LDL1;
run;

The following statements create the data set for the mean treatment difference and its associated standard error as a PARMS= data set, which will subsequently serve as an input data set for PROC SEQTEST. Note that all of the variables are required for a PARMS= data set, as described in the section PARMS= Data Set.

data Parms_LDL1;
   set Parms_LDL1;
   if Variable='Trt';
   _Scale_='MLE';
   _Stage_= 1;
   keep _Scale_ _Stage_ Variable Estimate StdErr;
run;

proc print data=Parms_LDL1;
   title 'Statistics Computed at Stage 1';
run;

Figure 84.9 displays the statistics computed at stage 1.

Since the sample sizes derived are based on the estimated variance at the designing phase, the information level that corresponds to the test statistic at stage 1 is estimated by

where is the standard error of the treatment estimate.

The following statements invoke the SEQTEST procedure to test for early stopping at stage 1:

ods graphics on;
proc seqtest Boundary=Bnd_LDL
             Parms(Testvar=Trt)=Parms_LDL1
             infoadj=prop
             ;
   ods output Test=Test_LDL1;
run;
ods graphics off;

The BOUNDARY= option specifies the input data set that provides the boundary information for the trial at stage 1, which was generated in the SEQDESIGN procedure. The PARMS=PARMS_LDL1 option specifies the input data set PARMS_LDL1 that contains the test statistic and its associated standard error at stage 1, and the TESTVAR=TRT option identifies the test variable TRT in the data set.

By default (or equivalently if you specify BOUNDARYKEY=ALPHA), the maximum information and the Type I error level are maintained. Furthermore, with the INFOADJ=PROP option (which is the default), the information levels at future interim stages (2 and 3) are adjusted proportionally from the levels provided in the BOUNDARY= data set.

The ODS OUTPUT statement with the TEST=TEST_LDL1 option creates an output data set named TEST_LDL1 which contains the updated boundary information for the test at stage 1, and the boundary information that is needed for the group sequential test at the next stage. See the section Boundary Adjustments for Information Levels for details.

The “Design Information” table in Figure 84.10 displays design specifications. By default (or equivalently if you specify BOUNDARYKEY=ALPHA), the boundary values are adjusted for the updated information levels to maintain the Type I level, and the maximum information remains the same as in the BOUNDARY= data set. But the derived Type II error probability and power are slightly different with new information levels. With the updated power , the corresponding fixed-sample design is also updated.

The “Test Information” table in Figure 84.11 displays the boundary values for the test statistic. By default (or equivalently if you specify BOUNDARYSCALE=STDZ), these statistics are displayed with the standardized Z scale. With the INFOADJ=PROP option (which is the default), information levels at future interim stages are derived proportionally from the corresponding levels provided in the BOUNDARY= data set.

At stage 1, the standardized Z statistic –0.44426 is between the lower and upper boundary values, and so the trial continues to the next stage. With the observed information level at stage 1, (which is not substantially different from the target information level at stage 1), the trial continues to the next stage without adjustment of the sample size according to the study plan.

If an observed information level is different from its target level at an interim stage, the sample sizes at future stages can be adjusted to achieve the target maximum information level according to the study plan. That is, a study plan might modify the final sample size to achieve the target maximum information level if the observed information level is different from its target level by a specified amount at the interim stage. For example, if the variance estimate is used to compute the required sample size of a two-sample Z test for mean difference, the study plan might use the current variance estimate to update the required sample size for the trial (Jennison and Turnbull, 2000, p. 295). See the section “Applicable Two-Sample Tests and Sample Size Computation” in “The SEQDESIGN Procedure” for a description of how to compute the sample size from the variance estimate.

If ODS Graphics is enabled, a detailed test plot with the rejection and acceptance regions is displayed, as shown in Figure 84.12. This plot displays the boundary values in the “Test Information” table in Figure 84.11. The stages are indicated by vertical lines with accompanying stage numbers. The horizontal axis indicates the information levels for the stages. As expected, the test statistic is in the continuation region between the lower and upper boundaries.

The following statements use the REG procedure with the data available at the first two stages to estimate the mean treatment difference and its associated standard error at stage 2:

proc reg data=LDL_2;
   model Ldl=Trt;
   ods output ParameterEstimates=Parms_LDL2;
run;

The following statements create and display (in Figure 84.13) the data set for the mean treatment difference and its associated standard error:

data Parms_LDL2;
   set Parms_LDL2;
   if Variable='Trt';
   _Scale_='MLE';
   _Stage_= 2;
   keep _Scale_ _Stage_ Variable Estimate StdErr;
run;

proc print data=Parms_LDL2;
   title 'Statistics Computed at Stage 2';
run;

Using the standard error for the treatment estimate available at stage 2, the information level that corresponds to the test statistic at stage 2 is estimated by

where is the standard error of the treatment estimate at stage 2.

The following statements invoke the SEQTEST procedure to test for early stopping at stage 2:

proc seqtest Boundary=Test_LDL1
             Parms(Testvar=Trt)=Parms_LDL2
             infoadj=prop
             ;
   ods output Test=Test_LDL2;
run;

The BOUNDARY= option specifies the input data set that provides the boundary information for the trial at stage 2, which was generated by the SEQTEST procedure at the previous stage. The PARMS= option specifies the input data set that contains the test statistic and its associated standard error at stage 2, and the TESTVAR= option identifies the test variable in the data set.

The ODS OUTPUT statement with the TEST=TEST_LDL2 option creates an output data set named TEST_LDL2 which contains the updated boundary information for the test at stage 2. The data set also provides the boundary information that is needed for the group sequential test at the next stage.

The “Test Information” table in Figure 84.14 displays the boundary values for the test statistic with the default standardized Z scale

At stage 2, the standardized test statistic, , is between its corresponding lower and upper boundary values. Therefore, the trial continues to the next stage.

The following statements use the REG procedure with the data available at the first three stages to estimate the mean treatment difference and its associated standard error at stage 3:

proc reg data=LDL_3;
   model Ldl=Trt;
   ods output ParameterEstimates=Parms_LDL3;
run;

The following statements create and display (in Figure 84.15) the data set for the mean treatment difference and its associated standard error:

data Parms_LDL3;
   set Parms_LDL3;
   if Variable='Trt';
   _Scale_='MLE';
   _Stage_= 3;
   keep _Scale_ _Stage_ Variable Estimate StdErr;
run;

proc print data=Parms_LDL3;
   title 'Statistics Computed at Stage 3';
run;

The following statements invoke the SEQTEST procedure to test for early stopping at stage 3:

ods graphics on;
proc seqtest Boundary=Test_LDL2
             Parms(Testvar=Trt)=Parms_LDL3
             infoadj=prop
             ;
   ods output Test=Test_LDL3;
run;
ods graphics off;

The BOUNDARY= option specifies the input data set that provides the boundary information for the trial at stage 3, which was generated by the SEQTEST procedure at the previous stage. The PARMS= option specifies the input data set that contains the test statistic and its associated standard error at stage 3, and the TESTVAR= option identifies the test variable in the data set.

The ODS OUTPUT statement with the TEST=TEST_LDL3 option creates an output data set named TEST_LDL3 which contains the updated boundary information for the test at stage 3. The data set also provides the boundary information that is needed for the group sequential test at the next stage.

The “Test Information” table in Figure 84.16 displays the boundary values for the test statistic with the default standardized Z scale.

The sequential test stops at stage 3 to reject the null hypothesis for the lower alternative because the test statistic –2.69289 is less than the corresponding upper boundary –2.25480. That is, the test demonstrates significant beneficial effect for the new drug.

The “Test Plot” displays boundary values for the design and the test statistic at the first three stages, as shown in Figure 84.17. It shows that the test statistic is in the “Rejection Region” below the lower boundary at stage 3.

When a trial stops, the “Parameter Estimates” table in Figure 84.18 displays the stopping stage, parameter estimate, unbiased median estimate, confidence limits, and p-value under the null hypothesis . As expected, the p-value 0.0108 is significant at the two-sided level, , and the confidence interval does not contain the value zero. The p-value, unbiased median estimate, and confidence limits depend on the ordering of the sample space , where k is the stage number and z is the standardized Z statistic. See the section Analysis after a Sequential Test for a detailed description of these statistics.